Arrowhead Pharmaceuticals (ARWR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- RNAi Therapeuticssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 13/100 (LOW), 61.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 8.76% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?
- ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases
- Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
- Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
- Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know
- Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier
- Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
- Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. — Ophthalmol Ther 2026 Sep 22 PMID 42771326
- One-year mortality, cardiovascular and limb events in the BEST-CLI Registry of chronic limb threatening ischemia patients. — J Vasc Surg 2026 Sep 16 PMID 42749068
- Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review. — Int J Chron Obstruct Pulmon Dis 2026 PMID 42741717
- Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial. — Nat Med 2026 Sep PMID 42717034
- Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. — Lancet Neurol 2026 Oct PMID 42716044
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Arrowhead Pharmaceuticals.
Full ARWR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.